Assessing Blood-Based Biomarkers to Define a Therapeutic Window for Natalizumab

Natalizumab is a monoclonal antibody that binds CD49d. Although it is one of the most effective treatments for Relapsing-Remitting Multiple Sclerosis (RRMS), a dosing regimen has not been optimized for safety and efficacy in individual patients. We aimed to identify biomarkers to monitor Natalizumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Granell-Geli, Júlia, Izquierdo-Gracia, Cristina, Sellés-Rius, Ares, Teniente-Serra, Aina, Presas-Rodríguez, Silvia, Mansilla, María José, Brieva, Luis, Sotoca, Javier, Mañé-Martínez, María Alba, Moral, Ester, Bragado, Irene, Goelz, Susan, Martínez-Cáceres, Eva, Ramo-Tello, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706232/
https://www.ncbi.nlm.nih.gov/pubmed/34945819
http://dx.doi.org/10.3390/jpm11121347

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706232/
https://www.ncbi.nlm.nih.gov/pubmed/34945819
http://dx.doi.org/10.3390/jpm11121347

Ejemplares similares